PARP1 and cervical cancer: In this study, we examined whether pharmacological or genetic abrogation of PARP-1 could confer enhanced CDDP sensitivity in two cervical cancer cell lines, HeLa (HPV 18 positive, adenocarcinoma) and SiHa (HPV 16 positive, squamous cell carcinoma).